Opens in a new tab
Thursday, 19 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

ANKTIVA

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in ANKTIVA

9 stories · every one Fact-Checked
ANKTIVA plus BCG for BCG-unresponsive high-grade papillary bladder cancer following expanded FDA approvalHealth TidingsImmunityBio Reports QUILT-2.005 Success for ANKTIVA Plus BCGImmunityBio announced that ANKTIVA plus BCG met the primary endpoint in the randomized QUILT-2.005 trial in BCG-naïve high-grade non-muscle invasive bladder cancer.12 Nov 2026 · 4 min read
Fact-Checked
ANKTIVA plus BCG combination therapy for BCG-unresponsive bladder cancer, showing durable responses and bladder preservationClinical TrialsANKTIVA Plus BCG Delivers Lasting Responses, with 84.2% Cystectomy-Free Survival at Three YearsLong-term findings from the QUILT-3.032 study show a 71% complete response rate with ANKTIVA plus BCG in BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.19 Oct 2026 · 4 min read
Fact-Checked
ANKTIVA plus BCG for BCG-unresponsive high-grade papillary bladder cancer following expanded FDA approvalNew Drug ApprovalFDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder CancerANKTIVA plus BCG for BCG-unresponsive high-grade papillary bladder cancer following expanded FDA approval…15 Oct 2026 · 4 min read
Fact-Checked
Illustration of ANKTIVA's mechanism of action demonstrating IL-15 receptor agonism, activation of JAK1/3-STAT5 and PI3K signaling pathways, immune cell proliferation, and anti-tumor cytotoxicity.New Drug ApprovalUAE Approves ANKTIVA for Bladder Cancer and Advanced Lung CancerThe UAE has approved ANKTIVA (nogapendekin alfa inbakicept) for adults with BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer after checkpoint inhibitor failure.1 Aug 2026 · 3 min read
Fact-Checked
anastasiia-gudantova-YOf9ZSwIrCs-unsplashHealth TidingsANKTIVA Plus BCG Shows Economic Edge in NMIBC CISPreliminary ISPOR 2026 findings suggest ANKTIVA® plus BCG may reduce healthcare costs while sustaining bladder‑preserving outcomes in BCG‑unresponsive NMIBC CIS.22 May 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_1lw8ct1lw8ct1lw8Health TidingsImmunityBio’s ANKTIVA sBLA for Papillary NMIBC Accepted by FDAImmunityBio announced FDA acceptance of its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG in patients with BCG‑unresponsive papillary non‑muscle invasive bladder cancer (NMIBC) without…20 May 2026 · 2 min read
Fact-Checked
Decorative cardboard illustration of person hand putting transparent dome on dollar banknotes and coins on blue backgroundHealth TidingsImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035ImmunityBio received five U.S. patents covering ANKTIVA + BCG combinations in non-muscle invasive bladder cancer, protecting treatment regimens, commercial kits, and clinical applications as the company advances Phase…19 May 2026 · 1 min read
Fact-Checked
khobar, saudi, arabia, east, gulf, saudi arabia, expat, raining, season, rainy, road, shade, saudi arabia, saudi arabia, saudi arabia, saudi arabia, saudi arabiaHealth TidingsImmunityBio Launches ANKTIVA in Saudi Arabia for Bladder and Lung CancerImmunityBio, Inc. has introduced ANKTIVA in Saudi Arabia for bladder and lung cancer indications, expanding immunotherapy access in the region after regulatory clearance by the Saudi Food and…21 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_1lw8ct1lw8ct1lw8Health TidingsImmunityBio Says ANKTIVA TV Ad Never Aired, Removes PodcastImmunityBio said it addressed FDA OPDP concerns tied to ANKTIVA promotional content, removed a podcast, and confirmed the referenced television advertisement was never broadcast.6 Apr 2026 · 2 min read
Fact-Checked
Page 1 of 1